A consortium of biopharmaceutical companies previously developed an optimised zebrafish developmental toxicity assay (ZEDTA) where chorionated embryos were exposed to non-proprietary test compounds from 5-6 hours post fertilization and assessed for morphological integrity at 5 days post fertilisation (dpf). With the original 20 test compounds, this achieved an overall predictive value for teratogenicity of 88% of mammalian in vivo outcome (Gustafson et al., 2012) . In the second phase of this project, 38 proprietary pharmaceutical compounds from four consortium members were evaluated in two laboratories using the optimized method using either pond-derived or cultivated-strain wild type zebrafish embryos at concentrations up to 100 µM. Embryo uptake of all compounds was assessed using LC-MSMS. 28/38 compounds had a confirmed embryo uptake of >5% and with these compounds the ZEDTA achieved an overall predictive value of 82% and 65% at the two respective laboratories. When low uptake compounds (≤5%) were retested with logarithmic concentrations up to 1000 µM, the overall predictivity across all 38 compounds was 79% and 62% respectively; with the 1 st laboratory achieving 74% sensitivity (teratogen detection) and 82% specificity (non-teratogen detection) and the 2 nd laboratory achieving 63% sensitivity (teratogen detection) and 62% specificity (nonteratogen detection). Subsequent data analyses showed that technical differences rather than strain differences were the primary contributor to inter-laboratory differences in predictivity. Based on these results, the ZEDTA harmonised methodology is currently being used for compound assessment at lead optimisation stage of development by 4/5 of the consortium companies.
INTRODUCTION
Developmental toxicants have traditionally been identified via in vivo studies in rodent and non-rodent species (usually the rabbit).
Although this in vivo testing paradigm is recognized as the gold standard in terms of assessing candidate drugs for human safety, (and is required by regulatory authorities), there are limitations in terms of assay throughput, test material requirements, timing and cost. Therefore, development of in vitro and in vivo screening assays (e.g. mouse embryonic stem [ES] cell test, FETAX (Frog Embryo Teratogenesis Assay Xenopus), zebrafish development and rat or rabbit whole embryo culture [WEC] to prioritize mammalian in vivo testing has been pursued by a number of groups (Paquette et al., 2008; Fort et al., 2004; Augustine-Rauch et al., 2010; Ellis-Hutchings and Carney, 2010) . In general, screening assays are capable of differentiating potent teratogens from non-teratogens, but tend to encounter difficulty with compounds whose teratogenic effects are equivocal . This has limited broad implementation of developmental toxicity screening assays and may be related to the fact that not all mechanisms of in vivo mammalian developmental toxicity can be readily mimicked using in vivo or in vitro screens (e.g. maternal metabolism, physiological differences and/or the attributes of drug exposure levels at critical times of gestation; van der Laan et al., 2012) . The Zebrafish Developmental Toxicity Assay (ZEDTA) is promising due to its simplicity of maintaining breeding pairs, rapid organogenesis and transparency of embryos. Importantly, zebrafish contain orthologues of 86% of drug targets and 70% of human genes which increases its potential as model for early identification of teratogenicity hazard, (Gunnarsson et al., 2008 , Howe et al., 2013 . ZEDTA models in vivo mammalian embryo foetal development studies in that intact embryos at the gastrulation stage are exposed to a concentration range of compound; then allowed to develop through the remainder of organogenesis and into an equivalent of a foetal stage. Larvae at 5 days post fertilisation (dpf) are assessed for overall viability and morphological integrity using a numerical score system .
A consortium of biopharmaceutical companies was formed in 2009 to develop a harmonized ZEDTA and to test the suitability of such an assay in early pharmaceutical development. In Phase I of this assessment 10 known teratogenic and 10 non-teratogenic non-proprietary compounds were assessed in a standard protocol in 4 different laboratories. The zebrafish embryo source reflected assay conditions across laboratories. Following the initial testing, the overall concordance to mammalian data across laboratories was between 60 and 70%. Subsequent optimization of the assay which focused on formulation and concentration adjustments and number of replicates resulted in improved concordance to 85% (Gustafson et al., 2012) .
In Phase II of this ZEDTA assessment, (reported within this manuscript), 38 proprietary pharmaceutical compounds (19 mammalian teratogenic and 19 mammalian non-teratogenic) were supplied by four members of the consortium. By systematically assessing the zebrafish assay with non-proprietary and then proprietary compounds the overall goal of this consortium was to develop a harmonised methodology as a means to determine the degree of overall concordance to in vivo mammalian data. The proprietary compounds, (sourced from R&D facilities with corresponding in vivo data) [Supplemental Table 1 and Supplemental Table 2 ], differs from previous inter-laboratory validation efforts where test compound selection was more limited (Genschow et al., 2002) . The pharmaceutical compounds included molecules that were structurally diverse with a variety of intended targets [Supplemental Table 3 ]. Full details of target and therapy area where still retained by each consortium member.
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The mammalian in vivo data for each compound in this study was based upon International Conference on Harmonisation guideline on tests for reproductive toxicity (ICH S5) and dose range finding embryo-foetal developmental toxicity studies in two species. The Zebrafish studies described in this manuscript were conducted in two laboratories of which one used a pond-derived strain and the other a cultivated zebrafish strain both using the optimized method to assess concordance across laboratories. When neither decreased viability nor developmental effects were observed following treatment with experimental compounds, uptake analysis of the compound was conducted to confirm appropriate exposure to the test material. Subsequently, this was followed by uptake analysis of all remaining compounds.
The Phase I and Phase II results were assessed to determine the degree of concordance to in vivo mammalian data and also considered its utility as part of a battery of in vivo or in vitro screening assays to facilitate early stage assessment for teratogenicity of pharmaceutical compounds under development.
MATERIALS AND METHODS

Study Design
This study evaluated a chorionated zebrafish embryo developmental toxicology assay previously described by the consortium (Gustafson et al., 2012) . Briefly, gastrulation stage embryos (5-6 hours post fertilization [hpf]) were exposed to a range of concentrations of the test compound and allowed to develop through the remainder of organogenesis period and into the larval stage. At 5 dpf, the larvae were assessed for overall viability and morphological integrity using a numerical score system . Briefly, a score of 5 to 0.5 was assigned to each morphological structure / organ to delineate malformed embryos from normal embryos. The morphological endpoints included somites, notochord, tail, fins, heart, facial structures (a score that includes assessment of eye, sacculi/otoliths and olfactory region), neural tube, and pharyngeal arches/jaw. A score of 5 was assigned to represent normal morphology, 4 was assigned to represent a slight variation from normal, 3 was assigned to represent a mild abnormality, 2 was assigned to represent a moderate malformation, 1 was assigned to represent a severe malformations and a score of 0.5 was assigned to represent missing structures .Thirty eight anonymous proprietary blinded compounds were run at 2 laboratories (Laboratory B and D [using laboratory nomenclature from Gustafson et al., 2012] ), with pond-derived and proprietary, cultivated zebrafish strain wild types. Positive and negative controls were included in each experiment (saccharin and all-trans-retinoic acid, respectively). Results were considered acceptable for inclusion in the inter-laboratory assessment if the following criteria were met:
1. Negative control treatments produced background malformation rates that were < historical control background malformation rates (< 16% or ≤ 2 affected embryo in negative control treatment groups from twelve embryos).
2. The lethality rate for media and DMSO controls was < 10 percent.
3. All experimental and formulation procedures were in alignment with the optimized protocol.
Experiments that did not meet the above criteria were repeated. Embryos exposed to the positive control at 0.01 µM responded with a very consistent pattern of malformations with most if not all endpoints affected. So for Phase II we only indicated whether each embryo was affected or not affected with the RA phenotype; as the main concern was for controlling for poor clutches as indicated by the media, solvent and saccharine controls.
Compound Test Set Selection
The 38 proprietary pharmaceutical compounds (19 teratogens and 19 non-teratogens) were provided by 4 of the pharmaceutical companies in the consortium. All of the compounds were previously assessed in embryo-foetal development (EFD) and/ or dose range finder (DRF) EFD studies in vivo in at least 2 mammalian species (Supplemental Table 1 and 2 detail maternal toxicity, foetal toxicity and foetal malformations)).
Compounds that were clearly teratogenic in either the DRF EFD studies or where an unequivocal signal was present in one EFD study were only assessed in 1 species. A compound was considered a teratogen if it induced visceral or skeletal structural abnormalities in the foetus at doses that caused no or only minimal to mild (maternal) toxicity. A compound was considered a non-teratogen if it was reported not to cause malformations in either of the 2 species evaluated. Compound 22 was accepted as an exception as it is an active ingredient of a pre-natal vitamin supplement which was assumed to be negative. The test set of 38 proprietary compounds had an equal distribution of teratogens and nonteratogens. This equal distribution was a means of balancing the positive and negative predictive values of the ZEDTA. The true distribution of teratogenic to non-teratogenic compounds in a drug discovery portfolio is not known. The compounds were structurally divergent with a molecular weight range (130-840 g/Mol), volume (polar surface area ranged between 125-630) and designed to have a potent binding affinity to drugable protein targets; see Supplemental Table 3 for physical chemical properties and whether the intended human target was present in the zebrafish.-
Animal care and egg production
Two laboratories (Laboratory B and D, nomenclature from Gustafson et al., 2012) participated in the assessment of the compounds for teratogenicity in this Phase II study. Laboratory B used wild type pond fish (Segrest Farms, Gibsonton, FL) while laboratory D used a proprietary cultivated zebrafish strain generated internally and originally obtained from Carolina Biological Supply Company (Burlington, NC).
Uptake assessment of the 38 compounds was carried out at laboratory C using a cultured WIK-strain (Wild-type India Kolkata). All three laboratories showed strong alignment in Phase I of the consortium effort. Due to timing and potential import restrictions the uptake was conducted on the strain previously tested in Phase I which was present at Laboratory C.
Breeding stocks of healthy, unexposed mature adult zebrafish were used for the production of fertilized eggs. Spawning zebrafish where maintained in a re-circulating husbandry system which varied by laboratory (Aquaneering, San Diego, CA -Laboratory B, Tecniplast, Germany -Laboratory C and Pharmacal Research Laboratory, Naugatuck, CT-Laboratory D). Water was maintained at approximately pH 7.35 (±0.65) and 28 (±1) °C. Fish were cultured in the aquarium facility with 14 hours light: 10 hours dark light cycle. Spawning and egg collection procedures were conducted as described previously by Gustafson et al., 2012 .
Experimental procedures
All procedures for the use of the optimised protocol including the culture of media and reagent, compound administration, viability assessment and morphological scoring are described in detail in Supplemental Materials I, Gustafson et al., 2012 and an optimized protocol reprinted here [Supplemental Materials I optimized protocol for Ring II 9[1].1.11]. Briefly, 5 hours post fertilisation embryos were exposed to test compounds at 0.1, 1, 10 and 100 µM, positive control (retinoic acid) at 0.01 µM, negative control (saccharin) at 100 µM, solvent (DMSO at 0.5% v/v) and media controls. Details of solubility, pH and embryo clutch information were also recorded. Exposed embryos (one per well in Corning Costar 24-well plates [3527] , |USA) were then incubated at 28 (±1) °C without solution change until assessment at 5 dpf in facility with 14 hours light: 10 hours dark light cycle.
Teratogenic Classification Procedures
A "teratogenic index", defined as the LC 25 / No Adverse Effect Level (NOAEL) ratio, was used to obtain a teratogenic classification of a compound. In earlier studies, LC 25 of 5 dpf zebrafish was selected as the optimum general toxicity value for the teratogenic index and the compound's half maximal inhibitory concentration (IC 50 ) value in NIH3T3 cells; a fibroblast cell line used as surrogate cell line for adult toxicity in developmental toxicology assays validated by ECVAM LC 25 studies reviewed in Brannen et al., 2010 supplemental materials). Subsequent work demonstrated that the LC 25 for viability in zebrafish was sufficient for supporting the teratogenic index so the cytotoxicity evaluations in the NIH3T3 surrogate cell line were not incorporated in the final teratogenic index supporting the dechorinated zebrafish assay . Likewise, the LC 25 represents the concentration of test compound capable of causing 25% lethality in 5 dpf embryos treated with a concentration range of compound and determined by curve fitting analysis (detailed in Supplemental Materials IIa in Gustafson et al., 2012) . . An LC 25 /NOAEL ratio ≥10 was considered a positive classification for in vivo teratogenic potential, whereas a ratio <10 was considered a negative classification. This ratio was identified as optimal for the correct classification of teratogenic potential of 31 definitive teratogens and non teratogens drawn from a range of industrial and consumer chemicals, pharmaceuticals, biocides and vitamins .
Determination of the Lowest Adverse Effect Level (LOAEL) and NOAEL involved assessing the concentration-response relationship of adverse morphological effects using the morphological score system described by Panzica-Kelly et al., 2010 . Consideration was given to the fact that some variation in morphology may occur in the controls. Therefore, to be considered compound-related, an adverse effect must exhibit both a concentration-response and occur at a frequency substantially higher than that observed in the concurrent controls or historical controls.
The LOAEL was considered the lowest employed concentration tested that produced compound-related malformations (morphological scores < 3) above levels observed in the vehicle and negative controls. The NOAEL was the next lowest concentration and exhibited compound-related anomalies (morphological score = 4) and malformations equal to or below those observed in the vehicle and negative controls. In cases where morphological anomalies occurred at a much higher frequency in the treatment groups compared to controls and a concentration-response was evident, such findings were also considered an adverse effect. When 100% lethality (with onset within 24 hours post fertilisation) was observed throughout the dosing range the compound was, by default, classified as a teratogen. This was based upon review of historical zebrafish assay data from two consortium laboratories (Laboratories A and D) that found that all compounds that caused 100% lethality through the 0.1 µM concentration were in vivo teratogens (Gustafson et al., 2012, Brannen et al., 2010 and unpublished data) . In addition, in none of the false positive compounds displayed this profile. However it is possible that other compounds (perhaps reactive intermediates, industrial and consumer chemicals or chemical agents used as pesticides and biocides etc) may have different profiles than pharmaceuticals and may not fit the criteria used in the present study. In cases where a compound produced a steep toxicity curve that led to limited concentrations to assess NOAEL, a subsequent experiment was performed with a refined dose range (see Supplemental Materials I optimized protocol for Ring II 9[1].1.11 reprinted from Gustafson et al., 2012) .
Compounds classified as non-teratogenic and which demonstrated less than 5% uptake were retested (using methods described above with the same compound administration procedures as described in Gustafson et al., (2012) ) at a higher concentration range (100, 500 and 1000 µM) to maximise the exposure of embryos to the test compounds and determine the final teratogenic classification. It should be emphasised that the assay design and prediction model described in this paper has evolved during work with pharmaceutical small molecules and before adapting these procedures to other types of compounds (industrial and consumer chemicals or chemical agents used as pesticides and biocides etc) one first needs to assess the performance of a larger repertoire of these chemicals in this assay.
Compound Uptake measurement in embryos
Following score assessment and before de-coding, the compounds were assessed for uptake analysis by liquid chromatography-tandem mass spectrometry (LC-MSMS) method as described in Gustafson et al., (2012) . Uptake chemical analysis was performed on extracted effluent from ~30 hpf embryos which had been exposed to the test compound for 24 hrs. Uptake was assessed at 1, 10 and 100 µM in embryo media containing 0.5 % DMSO for all compounds with the exception of compound numbers 19, 20, 27 and 38 which were assessed at 0.1, 1 and 10 µM due to previously demonstrated overt toxicity. Additionally, compound numbers 2 and 31 were only assessed at 1 and 10 µM due to unexpected overt toxicity to the embryos at 100 µM.
Compound uptake into the embryo was expressed as a percentage of nominal exposure concentration. This value was determined against the standard curve for each individual compound. The amount of compound present within a defined amount of solution (extracted from a defined number of embryos) was calculated against the calibration curve. This gave a concentration as a percentage of the test solution. As a general rule, results are expressed as high (>100%), medium (5-100%), or low (<5%) uptake relative to the test solution concentration.
Assay Performance Analysis
An assays performance was evaluated by generating contingency tables for Phase I and Phase II of the project. True positive (TP) and True negative (TN) compounds were compounds that had in vitro Zebrafish teratogenic classification that agreed with the in vivo mammalian data. False positive (FP) and false negative (FN) were compounds that had in vitro teratogenic classification that did not agree with in vivo mammalian data. The analyses included determining the following endpoints:
• Sensitivity for detecting teratogens: TP/(TP+FN) X 100
• Specificity for detecting non-teratogens: TN/(TN+FP) X 100
• Positive predictive value (PPV)-sensitivity for detecting teratogens: TP/(TP+FP) X 100
• Negative predictive value (NPV) -specificity for detecting non teratogens: TN/(TN+FN) X 100
• Overall predictivity: ((PPV+NPV)/2)
• Overall concordance: total number of compounds correctly classified /total number of compounds X 100
The assay's overall performance was evaluated in relation to the positive predictive value and the negative predictive value for correct classification of teratogens and non-teratogens, respectively.
Data Analysis
Prior to statistical analysis, the control average value dataset was tested for normality (Anderson-Darling Test) and homogeneity of variance (Bartlett's or Levene's Tests) using Minitab TM .
Non-parabolic data was tested using a Kruskal-Wallis test and compared using a MannWhitney test. Statistical significance between groups was indicated by a significance level of at least p<0.05.
RESULTS
Inter laboratory control assessment of background abnormalities and lethality
The negative control (DMSO, saccharine and untreated) score values at both testing laboratories were comparable. The group average morphological score values of the controls over >50 experiments ranged between 4.0-5.0 for both laboratories, with exception of 1 experiment at Laboratory D (Figure 1) . Overall average lethality in negative control groups was ≤1.15% for both laboratories. The majority of the 38 compounds had a LC 25 value of greater than 100 µM (Figure 2 ).
Phase II Results-comparison between laboratories
Laboratory B returned classifications for 38 compounds while laboratory D returned classifications for 37 compounds ( Table 1 and Supplemental Table 4 
Uptake analysis
Uptake of compounds into embryos was measured for all 38 compounds ( Table 1) . Twenty-six of the 38 compounds demonstrated a presence within the embryo at or above 5%, seven demonstrated uptake above the exposure concentration (> 100%) up to a maximum of over 20000% (200x the exposure concentration). Of the remaining twelve compounds; one showed a very high background (HB) level and the uptake in the embryo could not be determined; one could not be assessed for uptake because there was no appropriate ion for analysis (no ion detectable [NID]), the remaining ten compounds were defined as low uptake and showed either a low percentage uptake (< 5%) [n = 5] or the compound could not be detected (ND) [n = 5] within the embryo after 24 hours of exposure ( Table 1) . Of the eleven low uptake compounds (ND, NID and < 5%), four demonstrated morphologic abnormalities after a 5 day exposure and were classified as teratogenic by one or both laboratories. There was no observed grouping between the mammalian teratogenic classification and the uptake observed in the zebrafish (Figure 3) . Excluding the compounds which had either low uptake or were not detectable in the embryo after 24 hours of exposure, the predictivity and overall concordance of the assays in relation to mammalian in vivo classification conducted at laboratories B and D increased to 82% and 65%, respectively ( Table 2) .
Assay performance
Five compounds (four teratogens and 1 non teratogen [mammalian classification]) which presented no teratogenic signal and with < 5% uptake were anonymised a second time and re-tested at a higher concentration range (100, 500 and 1000 μM) in order to maximise uptake and determine the added value of inclusion of higher test concentrations. Previously, the 100 μM concentration was designated as a top concentration in order to maintain reasonable compound requirement and due to frequent precipitation and pH issues encountered when at or exceeding this concentration. Both laboratories correctly reclassified one compound as a teratogen and the others where classified as being nonteratogenic ( Table 1) . Inclusion of the high concentration experimental data improved the overall concordance to 74% and 60% for laboratories B and D, respectively ( Table 2) . Laboratory B demonstrated improved sensitivity to 63% while the specificity was not affected. Laboratory D also showed an increase in sensitivity and no effect on the specificity ( Table 2) .
Because of limited compound supply, four additional low uptake compounds classified as non teratogenic in the first study were retested at a separate laboratory (at 100, 500 and 1000 µM -Laboratory A using nomenclature from Gustafson et al., 2012) . These compounds included one teratogen and three non teratogens (footnoted on Table 1 ). All of these compounds were classified as non teratogenic, although the teratogenic compound exhibited signs of growth delay (yolk ball retention) at the highest concentration.
Further analysis of the high concentration results suggested the 100, 500 and 1000 μM range may potentially limit sensitivity due to the reduced chance for LC 25 /NOAEL ratios to achieve > 10. The entire test set, including the original 0.1-100 μM experiments were reevaluated using logarithmic concentrations (0.1, 1, 10, 100 and 1000 µM). With this approach, overall concordance to mammalian in vivo classification of Laboratory B improved to 79% with 74% sensitivity and 84% specificity ( Table 2) . Overall concordance of Laboratory D improved to 62% with 63% sensitivity and 62% specificity ( Table 2) .
As a means to determine whether strain differences in the LC 25 values were a cause of the disparity between the laboratories, Laboratory D was supplied with pond-derived breeder fish from laboratory B. The two strains were assessed simultaneously for both LC 25 value and morphological change for the 8 mismatched compounds. There were no observed zebrafish strain differences when tested at this one facility (data not shown).
DISCUSSION
The finalised ZEDTA assay incorporating replicate standards, logarithmic dose range (0.1 to 100 µM) and compound uptake assessment, demonstrated optimum concordance for the evaluation of a pharmaceutical compound's teratogenicity potential in relation to mammalian in vivo assessment. Higher dosing concentrations could be employed with compounds which demonstrated no lethality, morphological malformations and low uptake (< 5%).
Overall, the results showed that the ZEDTA had an overall concordance with mammalian in vivo classification of 65% (Lab D) and 82% (Lab B) when compound uptake of >5% could be demonstrated ( Table 2 ). In addition, when considering the logarithmic concentration analysis of the entire test set achieved a 62% (Lab D) and 79% (Lab B) concordance. Two limiting aspects of this zebrafish developmental toxicology assay include compound solubility limitations in the aqueous-based culture media and low uptake associated with some compounds.
The results of uptake analyses indicate that, uptake or lack of it affects the predictivity of the assay. Of the 38 pharmaceutical compounds assessed, 11 compounds presented low (<5%) or ND or NID uptake into the embryo. This issue was addressed by expanding the concentration range up to 1000 μM, which did increase sensitivity (identified some additional teratogens). However, it should be noted that retesting compounds may complicate study execution and interpretation of results due to the increased compound requirement and the need to optimize formulations to avoid precipitation and pH shifts. This could limit utility in certain cases.
During Phase I of this consortium effort laboratory B tested the optimized protocol in a training set of 10 teratogens and 10 nonteratogens which achieved 85% overall concordance (Gustafson et al., 2012) . Using this larger test set of 38 compounds as a form of cross-validation against the small non-proprietary training set; the results suggested a good stability between the two sets even though the test set was almost twice as large as the training set but still produced a concordance within 10% of the original training set.
Eight compounds had discordant teratogenic classifications between the two laboratories, similar to the rate of inter-laboratory variations in teratogenic classification observed in the training set (Gustafson et al., 2012) . Only five compounds showed a large variation between the observed LC 25 averages between the two laboratories (Figure 2) . Of the remaining compounds, when the lethality and scores were compared, the data was comparable for the most part, with only slight differences in lethality or mild malformation rates. Such differences may be due to zebrafish strain and/or technical variations between laboratories. An assessment of the mismatched compounds using both strains at Laboratory D showed no differences in both the LC 25 and the percentage of larvae displaying normal morphology (data not shown). This indicates a potential attribute of the assay in that it can achieve repeatable results using distinct zebrafish strains. Some of the differences may be related to slight formulation variations at one laboratory and not at another. An example of this is that four of the compounds had differences in observed precipitation between the labs on certain experiments, where slight differences in media temperature or pH might influence solubility.
Differences between the laboratories may also be related to biological variations (such as the quality of the clutches used in the assessment) or variations in how individual technicians assign scores; particularly when delineating an anomaly (score of 4) from a mild malformation (score of 3). Such variations in score assignment could potentially shift assignment of NOAEL to a different concentration. These slight differences can influence the LC 25 /NOAEL ratios to either a positive or negative teratogenic classification. In the future, simplification of the score system may reduce inter-lab variability, although it remains to be determined whether such a change would have an adverse effect on overall concordance.
As a means to have a comprehensive data set for analysis of the 38 compounds we maintained the original 0.5-5 score system as in the training set. Both the training and test sets employed in the assessment of the ZEDTA assay were equally balanced between teratogenic and nonteratogenic effects observed using the mammalian in vivo assessment. Due to the late stage positioning of mammalian in vivo teratogenicity assessment, the real incidence of teratogenic compounds during drug development stages are not known. Loong, (2003) demonstrated that depending on the incidence of an event (teratogencity) and using the specificity and sensitivity values, the positive and negative predicitive values of an assay can change. Using the specificity and sensitivity of Lab B (including low uptake compounds tested at higher concentration, 63% and 84%, respectively, Table 2 ) with a hypothesised incidence of teratogencity at 10%; the negative predictive value increased to 95%
(from 70%) and the positive predictive value decreased to 31% (from 70%). These alterations indicated that you would be 95% sure of a negative result but only 30% sure of a positive result if the incidence was 10% compared to an incidence of 50%. These alterations demonstrate the importance of a balanced training set and an understanding of the baseline incidence of the effect or endpoint you are assessing for.
Overall, this zebrafish assay presents comparable sensitivity to other in vitro assays. For instance, the standard battery of assays used to test genotoxicity of a range of chemicals for identification of carcinogens ranges from 59% (Ames test) to 79% (Micronucleus test) (Kirkland et al., 2005) . Additionally, in vivo embryo fetal development studies also present similar sensitivity to identifying human teratogens,
where the standard regulatory test species correctly identify about 61% (rat) or 41% (rabbit) human teratogens (Bailey et al., 2005) . In both cases, multiple assays are utilized to increase sensitivity in correct identification of carcinogens and teratogens. As such, combined use of rat and rabbit teratogenicity studies correctly identified about 74% of human teratogens (Supplemental Table 5 ).
Currently, other in vitro assays may provide useful alternatives to assess compounds with solubility or uptake limitations. For instance, the streamlined Whole Embryo Culture assay has similar predictivity to the more extensive ECVAM [European Union Reference Laboratory for alternatives to animal testing] assay (~80%). That assay uses a prediction model algorithm using data collected from only 1 test concentration (1 μM), at which precipitation is rarely encountered. In addition, the culture media contains 70% serum which can better represent the compounds' protein binding properties encountered in vivo and facilitate both solubility and delivery to the embryo (Kratz and Beyer, 1998; Augustine-Rauch et al 2004) . However, in some cases, certain compounds may not be stable in the presence of serum or become entirely protein-bound, leading to inhibited delivery and/or pharmacological activity in the embryo. In such cases, the ZEDTA is advantageous because of it being a serum-free assay..
The zebrafish assay may present its greatest strengths when it is applied in conjunction with other assays, where a final teratogenic classification is made following assessment of multiple assay data. Various in vitro developmental toxicology assays are available and may be suitable for assessing compounds for specific types of teratogenic liability or to be used routinely in a platform. Details associated with these assays are summarized in Supplemental Table 6 . This zebrafish assay could be compared to those achieved from other assays with a final classification based on a consideration of all results, with risk of teratogenic liability set according to the degree of teratogenic signal observed across multiple assays, which may help to rank different compounds from the same series.
The Environmental Protection Agency's ToxCast effort (for the identification and prioritisation of potential toxic chemicals) uses such an approach where multiple assay data are integrated in a computational systems biology approach for making classifications of various organ-based toxicity and teratogenic liabilities of chemicals and environmental agents (Dix et al, 2008) . Additionally, frequency analysis of teratogenic classifications ascertained from multiple developmental toxicology assay data have been found to enhance predictivity and assay tiering may have potential to improve results, turn around and overall predictivity (Stedman, Augustine-Rauch personal communications; unpublished results). For example, if uptake is not adequate, an additional higher concentration (1000 µM) could be included and if the final result presents no adverse effects on viability or morphology, other assays may be included to enhance predictivity in teratogenic classification, these could include rat whole embryo culture and/or embryonic stem cell culture assessment (van der Lann et al., 2012 Seiler et al., 2004; and Panzica-Kelly et al., 2013) ,.
The ZEDTA's culture work would benefit from automation, particularly image analysis; future efforts may also simplify the assay score assignments and applying statistical algorithms requiring fewer morphologic endpoints or reduced test concentrations. The current assay design achieved good predictivity and concordance. The assay has promising utility either as a stand-alone assay or in combination with other in vitro developmental toxicity assays such as embryonic stem cell assays, rat and/or rabbit embryo culture to enhance overall predictivity of teratogenic liability for pharmaceutical compounds. 
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